The non-peptide MAS-R agonist AVE0991 showed a significant decrease in the proliferation of MCF10A and ER− breast cancer cells, as well as the migration of the MCF10A, ER−, and ER+ cell lines, but did not alter the expression profile of the tested EMT markers. Here, MAS1L is linked to breast carcinoma.